Literature DB >> 23942740

[Abstracts at congresses of the German Society of Urology. Trends and quality].

J von Hardenberg1, T Worst, C Weiß, M S Michel.   

Abstract

BACKGROUND: The congress of the German Society of Urology is the third biggest urology congress worldwide and reflects the scientific landscape of urology in Germany. In the congress abstracts, detailed data regarding study design, current trends in urologic research and the cooperation of authors are lacking. We wanted to identify factors contributing to the likelihood of an abstract being followed by a publication in a peer-reviewed journal.
MATERIAL AND METHODS: The two congresses of the years 2002 and 2009 were exemplarily analyzed. Various aspects regarding study design and cooperations were retrieved from the abstracts and trends were determined. Subsequent publications in peer-reviewed journals were searched for in MEDLINE and potential factors influencing publication success were identified. Significance was tested for using the χ (2) and Mann-Whitney-U statistical tests.
RESULTS: A total of 732 abstracts (2002: 352, 2009: 380) were analyzed, one third of which contained prospective, retrospective or preclinical/experimental studies. Internal (28.7 %) and national (27.6 %) cooperations were most frequent. Significant trends towards more retrospective studies (p=0.008) and national cooperations (p=0.019) were found. Of the abstracts 49.2 % (2002) and 56.3% (2009) were followed by publication in peer-reviewed journals (median 15.1 months) with a significantly higher mean impact factor in 2009 (3.4 vs. 2.1, respectively p>0.0001). Therapeutic studies and those including statistics or national cooperations were significantly more likely to be published.
CONCLUSION: In the future urologic research should focus on prospective studies. Many abstracts are not followed by a publication in a peer-reviewed journal. This is especially true for abstracts containing no statistics. As national collaborations are correlated with successful publication, an early national networking of young researching urologists should be promoted.

Mesh:

Year:  2013        PMID: 23942740     DOI: 10.1007/s00120-013-3304-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  16 in total

1.  Under-reporting of clinical trials is unethical.

Authors:  Gerd Antes; Iain Chalmers
Journal:  Lancet       Date:  2003-03-22       Impact factor: 79.321

2.  Publication rate of abstracts presented at the annual meeting of the American Urological Association.

Authors:  Longena Ng; Karen Hersey; Neil Fleshner
Journal:  BJU Int       Date:  2004-07       Impact factor: 5.588

3.  [First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the Working Group Urological Oncology)].

Authors:  H Rexer
Journal:  Urologe A       Date:  2011-12       Impact factor: 0.639

4.  Publication rate of abstracts presented at the British Association of Urological Surgeons Annual Meeting.

Authors:  Amrith Raj Rao; John D Beatty; Marc Laniado; Hanif G Motiwala; Omer M A Karim
Journal:  BJU Int       Date:  2006-02       Impact factor: 5.588

5.  Fate of abstracts presented at the World Congress of Endourology: are they followed by publication in peer-reviewed journals?

Authors:  Riccardo Autorino; Giuseppe Quarto; Marco De Sio; Estevao Lima; Ernesto Quarto; Rocco Damiano; Rosario Oliviero; Luis Osorio; Filinto Marcelo; Massimo D'Armiento
Journal:  J Endourol       Date:  2006-12       Impact factor: 2.942

Review 6.  Full publication of results initially presented in abstracts.

Authors:  R W Scherer; P Langenberg; E von Elm
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

7.  A cohort study of summary reports of controlled trials.

Authors:  I Chalmers; M Adams; K Dickersin; J Hetherington; W Tarnow-Mordi; C Meinert; S Tonascia; T C Chalmers
Journal:  JAMA       Date:  1990-03-09       Impact factor: 56.272

8.  The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings.

Authors:  E D Saad; A Mangabeira; A L Masson; F E Prisco
Journal:  Ann Oncol       Date:  2009-08-28       Impact factor: 32.976

9.  Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

Authors:  Jan Lehmann; Margitta Retz; Christina Wiemers; Joachim Beck; Joachim Thüroff; Christoph Weining; Peter Albers; Detlef Frohneberg; Tanja Becker; Peter-Jörg Funke; Peter Walz; Sigrun Langbein; Frank Reiher; Matthias Schiller; Kurt Miller; Stephan Roth; Tilman Kälble; Donald Sternberg; Stefan Wellek; Michael Stöckle
Journal:  J Clin Oncol       Date:  2005-06-06       Impact factor: 44.544

10.  Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.

Authors:  Peter Albers; Roswitha Siener; Sabine Kliesch; Lothar Weissbach; Susanne Krege; Christoph Sparwasser; Harald Schulze; Axel Heidenreich; Werner de Riese; Volker Loy; Erhard Bierhoff; Christian Wittekind; Rolf Fimmers; Michael Hartmann
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

View more
  2 in total

1.  Current findings from research on structured abstracts: an update.

Authors:  James Hartley
Journal:  J Med Libr Assoc       Date:  2014-07

2.  Full publication of results initially presented in abstracts.

Authors:  Roberta W Scherer; Joerg J Meerpohl; Nadine Pfeifer; Christine Schmucker; Guido Schwarzer; Erik von Elm
Journal:  Cochrane Database Syst Rev       Date:  2018-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.